Explain this page
Arphra AIPlain-English read on Jazz Pharmaceuticals plc’s valuation06-03today
- Jazz Pharmaceuticals lung cancer drug fails main trial goal2d
- Jazz Pharmaceuticals Provides Update on Zepzelca® (lurbinectedin) Phase 3 LAGOON Trial in Second-Line Small Cell Lung Cancer2d
- Jazz Pharmaceuticals Provides Update on Zepzelca® (lurbinectedin) Phase 3 LAGOON Trial in Second-Line Small Cell Lung Cancer2d
- Why Jazz Pharmaceuticals (JAZZ) is a Top Value Stock for the Long-Term3d
AI Issuer Brief
Arphra AILoading cached brief…
Fair value
Football field →Weighted blend
—
— vs spot
Recommendation
n/a
0 of 0 methods
Method spread
0bull0bear
±5% threshold
Analyst PT consensus: $257.44 (+11.66%)
Price change · trailing returns
Live| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -2.38% | -2.70% | -0.21% | +29.13% | +37.65% | +35.62% | +110.29% | +82.19% | +23.68% | +55.32% | +1200.39% |
Insider · 30d
History →Bought
$0
0 txns
Sold
$0
0 txns
Net flow
+$0
Aftermarket
LiveLast trade
$232.00
50 sh
Bid
$210.94
100 sh
Ask
$250.00
10 sh
Spread
$39.060
Recent quarters
All financials →| Period | Revenue | Net income | EPS |
|---|
Analyst view
Consensus target
—
No price-target data returned for this ticker.
Recent actions
0 ↑0 ↓0 hold
- No recent grade actions.
News
DB · news_items- Jazz Pharmaceuticals lung cancer drug fails main trial goalreuters.com·Jun 12, 2026
- Jazz Pharmaceuticals Provides Update on Zepzelca® (lurbinectedin) Phase 3 LAGOON Trial in Second-Line Small Cell Lung Cancerprnewswire.com·Jun 12, 2026
- Jazz Pharmaceuticals Provides Update on Zepzelca® (lurbinectedin) Phase 3 LAGOON Trial in Second-Line Small Cell Lung Cancerprnewswire.com·Jun 12, 2026
- Why Jazz Pharmaceuticals (JAZZ) is a Top Value Stock for the Long-Termzacks.com·Jun 11, 2026
- Jazz Pharmaceuticals' New Cancer Drug Drives $1.3 Billion Opportunity, Says Analystbenzinga.com·Jun 10, 2026
- Why Is Jazz (JAZZ) Up 1% Since Last Earnings Report?zacks.com·Jun 04, 2026
- Jazz Pharmaceuticals to Present Comprehensive Data at SLEEP 2026 Highlighting Broad Treatment Effects of Xywav® (calcium, magnesium, potassium, and sodium oxybates) Oral Solution for People with Narcolepsy and Idiopathic Hypersomniaprnewswire.com·Jun 04, 2026
- Jazz Pharmaceuticals to Present Comprehensive Data at SLEEP 2026 Highlighting Broad Treatment Effects of Xywav® (calcium, magnesium, potassium, and sodium oxybates) Oral Solution for People with Narcolepsy and Idiopathic Hypersomniaprnewswire.com·Jun 04, 2026
Recent analyst activity
DB- Jun 10, 2026GradeBuy → BuyJazz Pharmaceuticals (JAZZ) PT Raised to $307 at BofA SecuritiesBank of America Securities
- Jun 09, 2026GradeMarket Perform → Market PerformBernstein SocGen Reiterates Market Perform Rating on Jazz Pharmaceuticals (JAZZ)Bernstein
- Jun 09, 2026PT$256.00Truist Securities Assumes Jazz Pharmaceuticals (JAZZ) at BuyTruist Financial
Peers
No peer list available for JAZZ.
Total assets
—
Total debt
—
Cash & equiv
—
Operating CF
—
Free cash flow
—
Buybacks
—
Recent insiders
All →| Insider | Action | Shares | Value | Date |
|---|---|---|---|---|
| No open-market insider activity in the recent window. | ||||
Income statement · annual
5y| Period | Revenue | Op income | Net income | EPS | Net margin |
|---|